Skip to main content

Emerging Infectious Diseases in Special Populations: Monkeypox and Meningococcus

AAHIVM Course Banner
Emerging Infectious Diseases in Special Populations: Monkeypox and Meningococcus

Module Description This webinar will provide the current state of the science of monkeypox and meningococcal disease, the disease epidemiology, available and emergent prevention and treatment options, and what should be considered and planned in response to this outbreak.

Credit Dates09/28/22 – 09/28/23
Learning Objectives
  • Describe the factors of previous and current Monkeypox outbreaks
  • Recognize the clinical presentation of Monkeypox symptoms
  • Delineate between the FDA-approved treatment options for Smallpox that may be clinically relevant for Monkeypox
  • Differentiate between the currently available Monkeypox vaccines
  • Identify suitable candidates for vaccination based on current guidelines
  • Describe the previous Meningitis outbreaks
  • Demonstrate the reason that an individual may need a vaccination for Meningitis

Target Audience This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers, are also encouraged to attend.

Richard Silvera, MD, MPH, CPH
Associate Program Director, Infectious Disease Fellowship
Assistant Professor of Infectious Diseases
Icahn School of Medicine at Mount Sinai

Method  of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity.
During the period September 28, 2022, through September 28, 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 17. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within four weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at or visit

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
The Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education (Universal Activity # JA4008162-9999-22-371-H02-P).
Type of Credit: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours, APRN 0.75 hours.

Disclosure of Conflict of InterestPostgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

Richard Silvera reports he receives grant/research support from the Bristol Myers Squibb Foundation.

The PIM planners have nothing to disclose.

The AAHIVM planners have nothing to disclose.

Media: Internet

Computer System Requirements: This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.

Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.